4D Molecular Therapeutics, Inc. Overview
Pro stress-test →4D Molecular Therapeutics designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions. The company leverages a proprietary platform called Therapeutic Vector Evolution that combines directed evolution with synthetic AAV capsid sequences to create targeted genetic medicines.
Strategic Profile
Pro stress-test →Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V.
Competitive Landscape
Pro stress-test →4D Molecular Therapeutics competes in the gene therapy sector against other AAV-based platforms and modalities. Key competitive areas include ophthalmology (competing with companies like Astellas and established biopharmaceutical players) and specialty rare diseases. The company's differentiation lies in its Therapeutic Vector Evolution platform enabling tailored AAV vector development.
Industry Context
4D Molecular Therapeutics, Inc. operates in Biotechnology - Gene Therapy.
Key facts
Founded: 2013 · Headquarters: Emeryville, California · Employees: 227 · Revenue: $120K · Market cap: $505M